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Poster Session II S355evaluated in a single 96-well plate, with a variable number and con-
figuration of samples within a group.
Results: The described multiplexed qPCR approach yielded results
which were comparable to those generated when using the assays in-
dividually. When the single assay algorithms were applied to the
samples tested in the multiplexed format, the same genotyping calls
were made and informative alleles identified.
Conclusions: Use of this RUO, multiplexed qPCR system for
screening of multiple specimens enabled rapid identification of in-
formative markers for all samples without post-PCR processing,
while dramatically decreasing sample volume requirements.408
DONOR AND RECIPIENT HBV IMMUNITY BEFORE TRANSPLANTATION SI-
MULTANEOUSLY AFFECTS THE ACQUISITION OF HBV IMMUNITY AFTER
UNRELATED-DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Luo, Y., Hu, Y., Shi, J., Tan, Y., Lai, X., He, J., Zheng, W., Cai, Z.,
Huang, H. The First Affliated Hospital, School of Medicine Zhejiang Uni-
versity, Hangzhou, Zhejiang, China
Introduction: Patients undergone allogeneic hematopoietic stem
cell transplantation (HSCT) are accompanied by intensive chemo-
therapy and immunosuppression. Such patients are in high risk of
hepatitis B virus (HBV) infection. Recovery of recipient immunity
on HBV post-transplantation has a potential role in HBV preven-
tion. In the current study, we performed a retrospective analysis of
recipient immunity on HBV after HSCT and attempted to find
out some factors associated with the HBV immunity acquisition
posttransplantation.
Patients and Methods: Between June 1999 and March 2009, 135
HBsAg(-) patients undergone unrelated HSCT were enrolled.
HBV serum markers including HBsAg, HBeAg, HBeAb, HBsAb
andHBcAbwere tested for donor screen and recipients. HBV immu-
nity was defined as positive HBsAb within 6 months posttransplan-
tation. Patients were divided into 4 groups (R+/D+, R+/D-, R-/D+
and R-/D-; R represents recipient and D represents donor) accord-
ing to + or -HBsAb in recipients and donors. The data were analyzed
using spss v17.0 software.
Results: Pretransplantation characteristics of patients and donors
were summarized in Table 1. Multivariate analysis showed that
primary disease type, donor and recipient’s sex and age, HLA dis-
parity and conditioning regimen containing ATG were not statisti-
cally different among the 4 groups. In total 42 of 42 (100%), 22 of 32
(68.8%), 24 of 26 (92.3%) and 0 of 35 (0%) patients acquired HBV
immunity posttransplantation in D+/R+, D+/R-, D-/R+ and D-/R-
group respectively (p\0.05 between D+/R+ and D+/R- group, D+/
R+ and D-/R- group, D+/R- and D-/R+ group, D+/R- and D-/R-
group, D-/R+ and D-/R- group) indicating HBsAb in both donors
and recipients had a significant favorable effect on maintaining the
HBV immunity of recipients with HBsAb before transplantation. A
total of 2 recipients experienced HBV reactivation post-
transplantation(1 in D-/R+ and D-/R- group each) indicating HBV
immunity in donors have protective effects on HBV reactivation.
The mean duration from stem cell transfusion to HBsAb appearance
was 25, 28, 20 and 24 days in the correspoinding group respectively
(p.0.05).
Conclusion:Our data support that donor and recipientHBV immu-
nity before transplantation can simultaneously affect the acquisition
of HBV immunity and have a vital role in HBV reactivation after un-
related-donor HSCT. HBV vaccination should be performed inTable 1. Pretransplantation Characteristics of Patients and donors
D+/R+ group D+/2 g
Median recipient age(years) 25 27
Male recipient number 27 20
Conditioning regimen containing ATG 5 3
Donor mean age 30 28
HLA mismatched 5 3
Positive HBcAb in recipients 12 8
Total number 42 32both donors and recipients who have no HBV immunity before
transplantation.409
STREAMLINED ANALYSIS, QUANTIFICATION AND LONG TERMMONITOR-
ING OF POST-BONE MARROW TRANSPLANT CHIMERISM STR DATA
Kristt, D.2, Snyder-Leiby, T.1, Hulce, D.1, Liu, J.1, Nguyen, P.1 1SoftGe-
netics, State College, PA; 2Hadassah Medical Center, Jerusalem, Israel
Over the last decade, hematopoietic stem cell transplantation
(HSCT) has become the main treatment for blood related and au-
toimmune diseases. After HSCT, chimerism monitoring plays
a critical role in predicting the effects of engraftment, GVHD
and disease relapse. We are introducing ChimerMarker software
which integrates raw data analysis to allele identification, chime-
rism quantification, reporting, and longitudinal monitoring. This
program eliminates the need for manual data transfer from geno-
typing software to chimerism analysis software and will automati-
cally identify informative loci using a patient specific
chimertyping panel. After identification, percent chimerism and
statistics for reliability assessment of each informative locus are cal-
culated. Average chimerism is calculated for all informative loci
that pass reliability assessment. Coefficient of variation, standard
deviation, margin of error and number of informative loci are re-
ported. Results can be printed. All samples and chimertyping panel
can be saved within one project file. Subsequent samples for a par-
ticular patient can be easily appended to the project file and quan-
tified within seconds. By having all test samples for one patient in
one file, the software can construct a longitudinal graph for long
term monitoring of chimeric status. This graph may be used to an-
ticipate changes in the chimerism state that may warrant drug in-
tervention to prevent GVHD or disease relapse. ChimerMarker
software is superior to the current method of using spreadsheets.
It eliminates error prone data transfer, time consuming manual
loci identification, repetitive calculations, and allows for electronic
record keeping of all samples, calculations, and longitudinal graph
in one project file. This study uses data collected from a five-year
post-bone marrow transplant patient. DNA was amplified using
Profiler Plus. Analysis, including: allele calls, determining infor-
mative loci, calculating percent chimerism and quality control met-
rics, and monitoring report graphing, was completed in
ChimerMarker in approximately 30 minutes.410
UTILIZATION OF NURSE PRACTITIONERS IN BONE MARROW HARVESTS
Turner, K.J., Tarin II, R. Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
Over 100 bone marrow transplants are performed at Cincinnati
Children’s Hospital Medical center each year. Those recipients for-
tunate enough to have a matched related donor number from ten to
twelve yearly. These donors are harvested at our facility through the
efforts of our harvest team comprised of two physicians and a nurse
practitioner. Bone marrow harvests require meticulous attention to
detail during the collection and post when the marrow is filtered
and transported to a processing center in preparation for infusion
into the recipient. Specifics about how the nurse practitioner func-
tions as a key member of the harvest team are outlined.before Transplantation
roup D2/R+ group D2/R2 group p value
28 27 >0.05
16 21 >0.05
4 3 >0.05
29 31 >0.05
4 3 >0.05
7 9 >0.05
26 35
